Does the Use of Peripheral Immune-Related Markers Indicate Whether to Administer Pazopanib, Trabectedin, or Eribulin to Advanced Soft Tissue Sarcoma Patients?
Does the Use of Peripheral Immune-Related Markers Indicate Whether to Administer Pazopanib, Trabectedin, or Eribulin to Advanced Soft Tissue Sarcoma Patients?
复制标题
DOI：
10.3390/jcm10214972
复制
发表时间：
2021-10-26
影响因子：
3.9
通讯作者：
Nakashima Y
中科院分区：
文献类型：
--
作者：
Shimada E;Endo M;Matsumoto Y;Tsuchihashi K;Ito M;Kusaba H;Nabeshima A;Nawata T;Maekawa A;Matsunobu T;Setsu N;Fujiwara T;Iida K;Nakagawa M;Hirose T;Kanahori M;Oyama R;Isobe T;Ariyama H;Kohashi K;Yamamoto H;Oda Y;Iwamoto Y;Akashi K;Baba E;Nakashima Y
帕唑帕尼、曲贝替丁和艾日布林用于治疗软组织肉瘤（STS）;然而，在临床环境中优先使用哪种药物方面几乎没有共识。本研究评估了外周免疫相关标志物在选择帕唑帕尼、曲贝替丁或艾日布林时是否可作为有用的参考。该研究纳入了63名患者，他们在2015年3月至2020年12月期间接受了帕唑帕尼，trabectedin或eribulin治疗晚期STS。根据这三种药物中给予的第一种药物，将患者分为三组。分析三组间总生存期（OS）或无进展生存期（PFS）的差异。首次给药的药物之间OS无显著差异。对于低嗜中性粒细胞/淋巴细胞比值（NLR）的患者，首选帕唑帕尼治疗的患者的OS短于其他患者（风险比[HR] = 9.53，95%置信区间[CI] = 1.94-18.13，p = 0.0018）。在低血小板/淋巴细胞比率（PLR）亚组中，艾日布林作为首选治疗的患者的OS较其他患者的OS长（HR = 0.32，95%CI = 0.10-0.98，p = 0.046）。因此，NLR和PLR可用作预后指标，以决定STS患者是否接受帕唑帕尼、曲贝替丁或艾日布林。
Pazopanib, trabectedin, and eribulin are administered for the treatment of soft tissue sarcomas (STSs); however, there is little consensus on which agent should be preferentially used in a clinical setting. This study assessed whether peripheral immune-related markers served as a useful reference when selecting pazopanib, trabectedin, or eribulin. This study included 63 patients who were administered pazopanib, trabectedin, or eribulin for advanced STSs between March 2015 and December 2020. Patients were divided into three groups based on the first drug administered among these three drugs. Differences in overall survival (OS) or progression-free survival (PFS) among the three groups were analyzed. OS showed no significant differences among the drugs administered first. For patients with low neutrophil-to-lymphocyte ratio (NLR), the OS of patients administered pazopanib as the first choice was shorter than the others (hazard ratio [HR] = 9.53, 95% confidence interval [CI] = 1.94–18.13, p = 0.0018). In the low platelet-to-lymphocyte ratio (PLR) subgroup, the OS of the patients administered eribulin for the first choice was longer than that of the others (HR = 0.32, 95%CI = 0.10–0.98, p = 0.046). Therefore, NLR and PLR might be used as prognostic indicators to dictate whether STS patients receive pazopanib, trabectedin, or eribulin.
登录
查看更多内容
影响因子：
4.7
作者：
Cheng, Yuan;Mo, Fei;Ma, Xuelei
通讯作者：
Ma, Xuelei
影响因子：
3.3
作者：
Nakaya A;Kurata T;Yoshioka H;Takeyasu Y;Niki M;Kibata K;Satsutani N;Ogata M;Miyara T;Nomura S
通讯作者：
Nomura S
影响因子：
2.5
作者：
Walsh, SR;Cook, EJ;Keeling, NJ
通讯作者：
Keeling, NJ
影响因子：
51.1
作者：
Kawai, Akira;Araki, Nobuhito;Takahashi, Shunji
通讯作者：
Takahashi, Shunji
影响因子：
2
作者：
Sato, Yasuyoshi;Nakano, Kenji;Takahashi, Shunji
通讯作者：
Takahashi, Shunji